<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14727">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00265330</url>
  </required_header>
  <id_info>
    <org_study_id>A1281133</org_study_id>
    <nct_id>NCT00265330</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)</brief_title>
  <official_title>26-Week Open-Label Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of ziprasidone during
      long-term open-label administration in children and adolescents (ages 10-17) with bipolar I
      disorder (manic or mixed)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Young Mania Rating Scale (YMRS) Total Score Change From Baseline</measure>
    <time_frame>baseline and 26 Weeks; 26 Weeks Last Observation Carried Forward (LOCF)</time_frame>
    <safety_issue>No</safety_issue>
    <description>YMRS: 11-item instrument with scales 0 (normal) to 4 (highest abnormal)for 7 items and 0 (normal) to 8 (highest abnormal) for 4 items. Total possible 0 - 60. Baseline is from parent study A1281132.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Severity (CGI-S) Change From Baseline</measure>
    <time_frame>baseline and 26 Weeks; 26 Weeks LOCF</time_frame>
    <safety_issue>No</safety_issue>
    <description>CGI-S Scale:standardized assessment tool to rate severity of subject's illness; assesses investigator's impression of subject's current illness state. Change: score at observation minus score at baseline. Score: 1 (not ill at all) to 7 (among most extremely ill). Baseline = last available observation from parent double-blind study(A1281132).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Lab Abnormalities</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>number of subjects with an abnormal lab value for those parameters with 5% or greater incidence of abnormality.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Low-Density Lipoprotein (LDL) Cholesterol and Fasting Cholesterol</measure>
    <time_frame>Week 6, Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: lab value at observation minus lab value at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Hormones</measure>
    <time_frame>Week 6, Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: lab value at observation minus lab value at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Supine Systolic Blood Pressure</measure>
    <time_frame>Week 1 through Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Supine Diastolic Blood Pressure</measure>
    <time_frame>Week 1 through Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Supine Pulse Rates</measure>
    <time_frame>Week 1 through Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Standing Systolic Blood Pressure</measure>
    <time_frame>Week 1 through Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Standing Diastolic Blood Pressure</measure>
    <time_frame>Week 1 through Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline in Standing Pulse Rates</measure>
    <time_frame>Week 1 through Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline for Body Weight</measure>
    <time_frame>Week 6, Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Mean change; body weight value at observation minus body weight value at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline for Body Mass Index (BMI) Z-Score</measure>
    <time_frame>Week 6, 26, early termination</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>mean change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI) Z-score Frequency</measure>
    <time_frame>Week 6</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Mass Index (BMI) Z-score Frequency</measure>
    <time_frame>Week 26</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline for QTcF Intervals</measure>
    <time_frame>Baseline to Week 26 (end of study)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QT intervals (observed in an electrocardiogram)corrected using Fridericia's formula (QTcF). Mean change: mean change of observation minus baseline. Baseline: last available observation in the parent double-blind study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Largest Categorical Increases in QTcF for Males</measure>
    <time_frame>Week 26 (end of study)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QT intervals (observed in an electrocardiogram) corrected with Fridericia's Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Largest Categorical Increases in QTcF for Females</measure>
    <time_frame>Week 26 (end of study)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QT interval (observed in an electrocardiogram) corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of Largest Categorical Increases in QTcF - All Subjects</measure>
    <time_frame>Week 26 (end of study)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QT intervals (observed in an electrocardiogram)corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Open</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone oral capsules</intervention_name>
    <description>Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .</description>
    <arm_group_label>Open</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participation in double-blind treatment study A1281132, meeting specific criteria of
             duration and safety

        Exclusion Criteria:

          -  Imminent risk of suicide or homicide, as judged by the site investigator;serious
             adverse event related to study medication in study A1281132; significant prolongation
             of QT interval in study A1281132.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <zip>32778</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96826</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Terre Haute</city>
        <state>Indiana</state>
        <zip>47802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Mississippi</state>
        <zip>39301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63044-2588</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267-0559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73116</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>DeSoto</city>
        <state>Texas</state>
        <zip>75115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <zip>77566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>West Allis</city>
        <state>Wisconsin</state>
        <zip>53227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A1281133&amp;StudyName=Safety%20and%20tolerability%20of%20ziprasidone%20in%20children%20and%20adolescents%20with%20bipolar%20I%20disorder%20%28manic%20or%20mixed%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2011</verification_date>
  <lastchanged_date>December 2, 2011</lastchanged_date>
  <firstreceived_date>December 12, 2005</firstreceived_date>
  <firstreceived_results_date>January 22, 2009</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The number of subjects entering this trial was determined by the number of subjects electing to continue treatment after completing or withdrawing from the preceding double-blind study (A1281132: NCT00257166).</recruitment_details>
      <pre_assignment_details>A total of 169 subjects from the parent study were assigned to the extension study and 162 continued on and received study treatment in the extension study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ziprasidone</title>
          <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Wanted to Start Psychotherapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family Scheduling Conflicts</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Began Taking Formulary Geodon</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discharged from Unit for Long Term Care</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Principal Investigators Request</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ziprasidone</title>
          <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="162"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13.3" spread="2.1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="90"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Young Mania Rating Scale (YMRS) Total Score Change From Baseline</title>
        <description>YMRS: 11-item instrument with scales 0 (normal) to 4 (highest abnormal)for 7 items and 0 (normal) to 8 (highest abnormal) for 4 items. Total possible 0 - 60. Baseline is from parent study A1281132.</description>
        <time_frame>baseline and 26 Weeks; 26 Weeks Last Observation Carried Forward (LOCF)</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Safety Analysis Set includes all subjects who took at least one dose of study medication in this open-label extension study. (Row: n=number subjects with observation)</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Young Mania Rating Scale (YMRS) Total Score Change From Baseline</title>
            <description>YMRS: 11-item instrument with scales 0 (normal) to 4 (highest abnormal)for 7 items and 0 (normal) to 8 (highest abnormal) for 4 items. Total possible 0 - 60. Baseline is from parent study A1281132.</description>
            <units>score on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 2 (n=153)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.8" spread="9.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 (n=122)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.0" spread="9.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.3" spread="12.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.1" spread="11.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="11.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26-LOCF (n=153)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.3" spread="10.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Global Impression of Severity (CGI-S) Change From Baseline</title>
        <description>CGI-S Scale:standardized assessment tool to rate severity of subject’s illness; assesses investigator’s impression of subject’s current illness state. Change: score at observation minus score at baseline. Score: 1 (not ill at all) to 7 (among most extremely ill). Baseline = last available observation from parent double-blind study(A1281132).</description>
        <time_frame>baseline and 26 Weeks; 26 Weeks LOCF</time_frame>
        <safety_issue>No</safety_issue>
        <population>The Safety Analysis Set includes all subjects who took at least one dose of study medication in this open-label extension study. (Row: n=number subjects with observation)</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Global Impression of Severity (CGI-S) Change From Baseline</title>
            <description>CGI-S Scale:standardized assessment tool to rate severity of subject’s illness; assesses investigator’s impression of subject’s current illness state. Change: score at observation minus score at baseline. Score: 1 (not ill at all) to 7 (among most extremely ill). Baseline = last available observation from parent double-blind study(A1281132).</description>
            <units>score on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=159)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.2" spread="0.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=150)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" spread="1.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6 (n=122)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=99)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=85)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="1.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="1.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=70)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.8" spread="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.1" spread="1.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=48)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26-LOCF (n=160)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="1.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Lab Abnormalities</title>
        <description>number of subjects with an abnormal lab value for those parameters with 5% or greater incidence of abnormality.</description>
        <time_frame>Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Total number of subjects with given laboratory test at given visit. Range: N=136-134, with the exception of Insulin (N=115)</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="136"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Incidence of Lab Abnormalities</title>
            <description>number of subjects with an abnormal lab value for those parameters with 5% or greater incidence of abnormality.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Bicarbonate (N=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="44"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine blood/Hemoglobin (N=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine ketones (N=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Testosterone (N=134)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine specific gravity (N=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine red blood cells (N=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Monocytes (N=134)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Triglycerides (N=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Urine white blood cells (N=136)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insulin (N=115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Low-Density Lipoprotein (LDL) Cholesterol and Fasting Cholesterol</title>
        <description>Mean Change: lab value at observation minus lab value at baseline.</description>
        <time_frame>Week 6, Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The Safety Analysis Set includes all subjects who took at least one dose of study medication in this open-label extension study. (Row: n= total number of subjects with at least 1 observation of the given laboratory test.)</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="134"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Low-Density Lipoprotein (LDL) Cholesterol and Fasting Cholesterol</title>
            <description>Mean Change: lab value at observation minus lab value at baseline.</description>
            <units>milligram /deciliter (mg/dL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>LDL cholesterol Week 6 (n=113)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.5" spread="19.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL cholesterol Week 26 (n=59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.9" spread="19.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>LDL cholesterol Early Termination (n=44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.6" spread="20.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fasting cholesterol Week 6 (n=113)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-7.7" spread="21.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fasting cholesterol Week 26 (n=59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-10.3" spread="22.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fasting cholesterol Early Termination (n=44)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.6" spread="24.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Hormones</title>
        <description>Mean Change: lab value at observation minus lab value at baseline</description>
        <time_frame>Week 6, Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>The Safety Analysis Set includes all subjects who took at least one dose of study medication in this open-label extension study. (Row: n= total number of subjects with at least 1 observation of the given laboratory test.)</population>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="131"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Hormones</title>
            <description>Mean Change: lab value at observation minus lab value at baseline</description>
            <units>nanogram/deciliter (ng/dL)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Testosterone Week 6 (n=80)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.9" spread="84.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Testosterone Week 26 (n=38)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-23.4" spread="112.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Testosterone Early Termination (n=32)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="61.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin Week 6 (n=110)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.7" spread="13.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin Week 26 (n=59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.9" spread="8.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Prolactin Early Termination (n=40)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="11.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insulin-like growth factor Week 6 (n=95)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-19.9" spread="63.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insulin-like growth factor Week 26 (n=47)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-9.2" spread="68.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Insulin-like growth factor Early Term (n=34)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-8.4" spread="66.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Supine Systolic Blood Pressure</title>
        <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
        <time_frame>Week 1 through Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in Supine Systolic Blood Pressure</title>
            <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
            <units>millimeters of mercury (mm Hg)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=155)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="11.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" spread="10.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/pre-dose (n=115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="9.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/5-7 hours post dose (n=108)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="9.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=93)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="10.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=82)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="10.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.4" spread="11.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.7" spread="10.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9" spread="11.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="11.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Supine Diastolic Blood Pressure</title>
        <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
        <time_frame>Week 1 through Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in Supine Diastolic Blood Pressure</title>
            <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
            <units>millimeters mercury (mm Hg)</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=155)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.5" spread="8.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="8.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/pre-dose (n=115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.6" spread="9.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/5-7 hours post dose (n=108)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="8.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=93)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.4" spread="10.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=82)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.4" spread="8.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.6" spread="9.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.7" spread="9.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="10.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="8.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Supine Pulse Rates</title>
        <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
        <time_frame>Week 1 through Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in Supine Pulse Rates</title>
            <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
            <units>beats per minute</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=155)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="12.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=142)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="11.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/pre-dose (n=115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.8" spread="11.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/5-7 hours post dose (n=108)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.0" spread="12.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=93)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="11.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=82)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.0" spread="12.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.5" spread="12.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=69)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.1" spread="11.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.0" spread="11.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.9" spread="13.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Standing Systolic Blood Pressure</title>
        <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
        <time_frame>Week 1 through Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in Standing Systolic Blood Pressure</title>
            <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
            <units>mm Hg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=154)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="10.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=141)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.7" spread="11.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/pre-dose (n=115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="9.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/5-7 hours post dose (n=108)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="9.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=93)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.4" spread="11.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=82)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="11.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.1" spread="10.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=70)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.2" spread="10.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.6" spread="10.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" spread="11.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Standing Diastolic Blood Pressure</title>
        <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
        <time_frame>Week 1 through Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in Standing Diastolic Blood Pressure</title>
            <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
            <units>mm Hg</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=154)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.7" spread="9.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=141)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" spread="9.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/pre-dose (n=115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="9.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/5-7 hours post dose (n=108)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="9.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=93)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="10.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=82)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.1" spread="9.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" spread="8.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=70)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="8.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.8" spread="8.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.4" spread="10.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline in Standing Pulse Rates</title>
        <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
        <time_frame>Week 1 through Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="161"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline in Standing Pulse Rates</title>
            <description>Mean Change: vital sign value at observation minus vital sign value at baseline</description>
            <units>beats per minute</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=154)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.5" spread="14.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=140)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.9" spread="13.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/pre-dose (n=115)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.3" spread="13.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/5-7 hours post dose (n=108)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.8" spread="13.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=93)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.6" spread="14.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=82)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.5" spread="14.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.3" spread="12.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=70)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.2" spread="14.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.9" spread="12.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=75)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.8" spread="13.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline for Body Weight</title>
        <description>Mean change; body weight value at observation minus body weight value at baseline.</description>
        <time_frame>Week 6, Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline for Body Weight</title>
            <description>Mean change; body weight value at observation minus body weight value at baseline.</description>
            <units>kilogram</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 6 (n=119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.3" spread="3.0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.9" spread="5.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.4" spread="2.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline for Body Mass Index (BMI) Z-Score</title>
        <description>mean change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
        <time_frame>Week 6, 26, early termination</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline for Body Mass Index (BMI) Z-Score</title>
            <description>mean change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
            <units>score on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 6 (n=119)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="0.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.1" spread="0.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.0" spread="0.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Mass Index (BMI) Z-score Frequency</title>
        <description>change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
        <time_frame>Week 6</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Body Mass Index (BMI) Z-score Frequency</title>
            <description>change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&lt;-4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-4 to &lt;-3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-3 to &lt;-2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-2 to &lt;-1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-1 to &lt;0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥0 to &lt;1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="61"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥1 to &lt;2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥2 to &lt;3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥3 to &lt;4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Mass Index (BMI) Z-score Frequency</title>
        <description>change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
        <time_frame>Week 26</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Body Mass Index (BMI) Z-score Frequency</title>
            <description>change in body weight BMI -Z score calculated by subtracting median reference value of the population from observed value and dividing by standard deviation of reference population (kg/m squared). 0=no change</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>&lt;-4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-4 to &lt;-3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-3 to &lt;-2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-2 to &lt;-1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥-1 to &lt;0</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="27"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥0 to &lt;1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥1 to &lt;2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥2 to &lt;3</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥3 to &lt;4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥4</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline for QTcF Intervals</title>
        <description>QT intervals (observed in an electrocardiogram)corrected using Fridericia’s formula (QTcF). Mean change: mean change of observation minus baseline. Baseline: last available observation in the parent double-blind study.</description>
        <time_frame>Baseline to Week 26 (end of study)</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="162"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change From Baseline for QTcF Intervals</title>
            <description>QT intervals (observed in an electrocardiogram)corrected using Fridericia’s formula (QTcF). Mean change: mean change of observation minus baseline. Baseline: last available observation in the parent double-blind study.</description>
            <units>millisecond</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Week 1 (n=152)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.8" spread="18.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 2 (n=137)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.5" spread="17.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/pre-dose (n=111)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.6" spread="17.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 6/5-7 hours post dose (n=107)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.0" spread="18.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 10 (n=91)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.3" spread="18.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 14 (n=81)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.2" spread="17.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 18 (n=73)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.4" spread="15.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 22 (n=68)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.1" spread="16.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Week 26 (n=64)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.1" spread="15.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Early Termination (n=45)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.7" spread="17.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Largest Categorical Increases in QTcF for Males</title>
        <description>QT intervals (observed in an electrocardiogram) corrected with Fridericia's Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
        <time_frame>Week 26 (end of study)</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Largest Categorical Increases in QTcF for Males</title>
            <description>QT intervals (observed in an electrocardiogram) corrected with Fridericia's Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>≥450 msec (millisecond )</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥460 msec</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥480 msec</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥30 msec increase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥60 msec increase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Largest Categorical Increases in QTcF for Females</title>
        <description>QT interval (observed in an electrocardiogram) corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
        <time_frame>Week 26 (end of study)</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Largest Categorical Increases in QTcF for Females</title>
            <description>QT interval (observed in an electrocardiogram) corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>≥450 msec (millisecond)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥460 msec</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥480 msec</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥30 msec increase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥60 msec increase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Frequency of Largest Categorical Increases in QTcF - All Subjects</title>
        <description>QT intervals (observed in an electrocardiogram)corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
        <time_frame>Week 26 (end of study)</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone</title>
            <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="160"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Frequency of Largest Categorical Increases in QTcF - All Subjects</title>
            <description>QT intervals (observed in an electrocardiogram)corrected using Fridericia Formula (QTcF). Number of subjects with corresponding categorical increase in QTcF.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>≥450 msec (millisecond)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥460 msec</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥480 msec</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥30 msec increase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>≥60 msec increase</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment emergent adverse events are reported from time of first dose of study treatment up to 6 days after last dose of study treatment.</time_frame>
      <desc>Safety population = all randomized subjects with at least 1 dose of study treatment. An Adverse Event (AE) term may be reported as both a serious and non-serious AE, but are distinct events. AE may = serious for 1 subject and = non-serious for another subject or subject may have experienced both a serious and non-serious episode of the same event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone</title>
          <description>Dosing was flexible, with dosing adjustments made at the discretion of the investigator to maintain optimal efficacy and tolerability. For subjects having a body weight of 45 kilograms (kg) or greater, the target dosage range was 40-80 milligrams (mg) twice per day (BID) (80-160 mg/day). For subjects having a body weight under 45 kg, the maximum permitted dose was 80 mg/day (40 mg BID).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Hallucinations, mixed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Negative thoughts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Oppositional defiant disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Self-injurious behavior</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="162"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="162"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The AE tables were amended to incorporate previously unreported AEs that were found during an independent audit and verified by the investigators.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
